PacBio and Bluebee launch de novo genome assembly pipeline on the Bluebee analysis platform

Rijswijk, The Netherlands and Menlo Park, USA: 9 October 2017 - Bluebee, a company driving genomic data-driven medicine, and Pacific Biosciences of California, Inc. (NASDAQ: PACB), the leader in long-read sequencing, announced they have integrated the PacBio® de novo assembly pipeline onto the Bluebee® genomics analysis platform. The integration creates a simplified workflow and fully automated, end-to-end data analysis solution that allows assembly of any size genome, including the human genome. Bluebee's platform provides a user-friendly environment that does not require specialized bioinformatics knowledge. The solution will be launched next week at the American Society of Human Genetics (ASHG) annual meeting in Orlando, FL.

More info on Bluebee's website


Next > Capricorn Venture Partners makes first investment from its Capricorn Sustainable Chemistry Fund and completes ViroVet’s series A funding

Previous > Sequana Medical announces publication of results of alfapump® Multicentre, Post-Marketing Surveillance Registry in Alimentary Pharmacology & Therapeutics (AP&T).